中文
Home
|
Set As Homepage
News
About us
Over View
Enterprise Culture
History
Organization
Health & Wellness
Women Health & Wellness
Popular contraceptive methods
Products
Dietary Supplement
Women Healthcare Products
Contraceptives
Medical Abortion
Hormone Replacement Therapy
Endometriosis
Ophthalmology Medicines
APIs and Intermediates
APIs
Intermediates
Anesthetic
Biological Agents
Respiratory medicine
R & D
Product R&D
Authentication
Foreign Affairs
Introduction
Foreign Cooperation
Business Scope
Contact Us
Our News
2011 China Health Annual Billboard
2012-1-30
Qinhuangdao Zizhu rewarded the API GMP
2012-1-12
API GMP for Testosterone
2012-1-12
Zizhu has been rewarded the OHSAS18001 certificate by TÜVAnlagent...
2011-8-16
Zizhu passed the reevaluation of the ISO9001:2000 quality system on No...
2011-8-16
Zizhu pharmaceutical obtained ISO10012 certificate
2011-8-16
Levonorgestrel Tablets(0.75mg) and Mifepristone were awarded the “ Fa...
2011-8-16
Zizhu successfully passed the ISO14001 environmental system reevaluati...
2011-8-16
Industry News
Contraceptives: A Global Strategic Business Report
2011-8-22
Contraceptive Market To 2016
2011-8-22
Contraceptive prevalence
2011-8-22
Hormone Replacement Therapy (HRT): A Global Strategic Business Report
2011-8-22
Top News
Qinhuangdao Zizhu rewarde...
QZP Awarded the API GMP
API GMP for Testosterone...
API GMP for Testosterone
Contact:
Tel: +86-10-62250847 Fax: +86-10-62245401
E-Mail:
zizhu@zizhu-pharm.com
Beijing
Zizhu
Pharmaceutical Co.,Ltd
Home
|
News
|
About us
|
Health & Wellness
|
Products
|
R & D
|
Foreign Affairs
Copyright© 2011-2021
